These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1419818)

  • 21. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
    Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
    Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation.
    Fridrik MA; Wahl G; Herbinger W
    Blut; 1988 Dec; 57(6):357-60. PubMed ID: 3207893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Successful induction chemotherapy for childhood RAEB-T with VP-16: a case report].
    Tanizawa A; Sonomura T; Wakazono Y; Akiyama Y; Kubota M; Mikawa H
    Rinsho Ketsueki; 1989 Jul; 30(7):1052-7. PubMed ID: 2810790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
    Philpott N; Mehta J; Treleaven J; Powles R
    Leuk Lymphoma; 1994 Sep; 15(1-2):127-30. PubMed ID: 7858489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Serum proteomics in patients with RAEB myelodysplastic syndromes].
    Zhong LY; Liu TH; Li YQ; Geng SX; Lu ZS; Weng JY; Wu SJ; Luo CW; Du X
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Sep; 29(9):1799-801. PubMed ID: 19778794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cyclosporine A based therapy for myelodysplastic syndrome].
    Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
    Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Mancini M; Alimena G
    Leuk Lymphoma; 2012 Aug; 53(8):1558-60. PubMed ID: 22280532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
    Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
    Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
    Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
    Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
    Guan M; Chen SC; Li RS; Ge CW; Zhu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
    Hast R; Hellström-Lindberg E; Ohm L; Björkholm M; Celsing F; Dahl IM; Dybedal I; Gahrton G; Lindberg G; Lerner R; Linder O; Löfvenberg E; Nilsson-Ehle H; Paul C; Samuelsson J; Tangen JM; Tidefelt U; Turesson I; Wahlin A; Wallvik J; Winquist I; Oberg G; Bernell P
    Leukemia; 2003 Sep; 17(9):1827-33. PubMed ID: 12970783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low dose Ara-C for patients with myelodysplastic syndromes.
    Powell BL; Capizzi RL; Jackson DV; Richards F; Muss HB; Lyerly ES; Rosenbaum DL; Connelly RA; Buss DH; Bearden JD
    Leukemia; 1988 Mar; 2(3):153-6. PubMed ID: 3347093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
    Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
    Zhang Z; Xie J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan.
    Shimamoto T; Tohyama K; Okamoto T; Uchiyama T; Mori H; Tomonaga M; Asano Y; Niho Y; Teramura M; Mizoguchi H; Omine M; Ohyashiki K
    Leuk Res; 2003 Sep; 27(9):783-8. PubMed ID: 12804635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of myelodysplastic syndrome with cyclosporin A.
    Chen S; Jiang B; Da W; Gong M; Guan M
    Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.